International Immunopharmacology, Journal Year: 2025, Volume and Issue: 151, P. 114369 - 114369
Published: March 2, 2025
Language: Английский
International Immunopharmacology, Journal Year: 2025, Volume and Issue: 151, P. 114369 - 114369
Published: March 2, 2025
Language: Английский
Drug Design Development and Therapy, Journal Year: 2025, Volume and Issue: Volume 19, P. 1357 - 1375
Published: Feb. 1, 2025
Bone and cartilage diseases are significantly associated with musculoskeletal disability. However, no effective drugs available to cure them. FOXO3a, a member of the FOXO family, has been implicated in cell proliferation, ROS detoxification, autophagy, apoptosis. The biological functions FOXO3a can be modulated by post-translational modifications (PTMs), such as phosphorylation acetylation. Several signaling pathways, MAPK, NF-κB, PI3K/AKT, AMPK/Sirt1 have development bone mediating expression FOXO3a. In particular, acts transcriptional factor various genes, MnSOD, CAT, BIM, BBC3, CDK6. plays critical role metabolism cartilage. this article, we mainly discussed diseases, osteoporosis (OP), osteoarthritis (OA), rheumatoid arthritis (RA), ankylosing spondylitis (AS), intervertebral disc degeneration (IDD). promote osteogenic differentiation, induce osteoblast inhibit osteoclast activity, suppress chondrocyte apoptosis, reduce inflammatory responses. Collectively, up-regulation shows beneficial effects, become potential target for diseases.
Language: Английский
Citations
0International Immunopharmacology, Journal Year: 2025, Volume and Issue: 151, P. 114369 - 114369
Published: March 2, 2025
Language: Английский
Citations
0